Drug Trial Radar · NCT06350825
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Last checked: Nov 19, 2026Latest source record: Apr 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 1, 2016
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Conditions
- Metastatic Prostate Cancer
- Therapy, Directly Observed
Interventions
Cytoreductive prostatectomy or brachytherapyProcedure
local treatment+SOC for metastatic prostate cancer
ADT+second-generation antiandrogens ± chemotherapyDrug
SOC(Triplet or doublet therapy) for mHSPC
Primary outcomes
What the sponsor says the trial is designed to measure.
- rPFSTime frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.